Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 8,628 Shares

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 8,628 shares of Omada Health stock in a transaction on Friday, August 7th. The stock was sold at an average price of $21.85, for a total transaction of $188,521.80. Following the transaction, the chief executive officer directly owned 411,861 shares of the company’s stock, valued at approximately $8,999,162.85. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Omada Health Price Performance

Shares of OMDA opened at $24.01 on Wednesday. The company’s 50-day moving average is $20.61 and its 200-day moving average is $16.32. The firm has a market capitalization of $1.47 billion, a PE ratio of 480.20 and a beta of 1.73. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. Analysts predict that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Institutional Trading of Omada Health

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC bought a new position in Omada Health in the second quarter valued at approximately $637,000. Walleye Capital LLC bought a new stake in Omada Health during the second quarter worth $458,000. Ilex Capital Partners UK LLP acquired a new stake in shares of Omada Health in the 2nd quarter valued at $201,000. Soros Fund Management LLC bought a new position in shares of Omada Health in the 2nd quarter valued at $640,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Omada Health during the 2nd quarter worth $32,000.

Analysts Set New Price Targets

Several analysts recently issued reports on OMDA shares. Citizens Jmp boosted their price target on Omada Health from $21.00 to $27.00 and gave the company a “market outperform” rating in a research note on Monday, July 20th. BTIG Research boosted their target price on shares of Omada Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Canaccord Genuity Group raised their price target on shares of Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Citigroup reiterated an “outperform” rating on shares of Omada Health in a research note on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.67.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.